DefinitionThis section has been translated automatically.
Pharmacodynamics (Effect)This section has been translated automatically.
You might also be interested in
IndicationThis section has been translated automatically.
Pregnancy/nursing periodThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Apply 2 times / day to the affected area. After healing in chronic eczema, move to proactive therapy 2 times / week on the chronic eczema sites.
Undesirable effectsThis section has been translated automatically.
ContraindicationThis section has been translated automatically.
PreparationsThis section has been translated automatically.
Note(s)This section has been translated automatically.
Cave! Although Pimecrolimus is not genotoxic up to now, an FDA warning letter was published in March 2005: In animal experimental studies in mice it was shown that the topical application of Pimecrolimus can potentially lead to a reduction of the local immune response. Further studies ("repeat dose studies") in mice showed a dose- and therapy-dependent development of lymphomas. Dose-dependent carcinogenicity studies with perorally applied Pimecrolimus showed a dose- and therapy-dependent development of lymphomas and benign thymomas. Since 2006 the US-American product information carries a particularly emphasized warning notice (black box) in which the lack of knowledge about the long-term safety of the products regarding the development of skin cancer and lymphomas is explicitly pointed out.
- It is recommended:
- Use Pimecrolimus only according to the authorization in case of atopical eczema.
- Use Pimecrolimus as second-line therapy in case of ineffectiveness or intolerance of first-line therapies.
- Do not use Pimecrolimus in children < 2 years.
- Use Pimecrolimus only for a short time (as short as possible) and intermittently but not as a permanent therapy.
- Do not use Pimecrolimus in combination with UV-therapies.
- After market introduction of the drugs, the occurrence of lymphomas was observed in patients who were treated topically with calcineurin inhibitors and steroids. However, this could not be confirmed in a subsequent study.
- In the case of psoriasis inversa, clinical improvements after topical application of Pimecrolimus ( off-label-use) (see calcineurin inhibitors) showed in individual cases.
LiteratureThis section has been translated automatically.
- Arellano FM et al (2006) Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis. J Invest Dermatol (epub)
- Eichenfield LF et al (2003) Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 111: 1153-1168
- Ortiz-Urda S, Rappersberger K (2003) New immunosuppressive agents for treating psoriasis. dermatologist 54: 230-236
- Rappersberger K (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876-887
- Ständer S et al (2003) Antipruritic effects of pimecrolimus and tacrolimus. dermatologist 54: 413-417
- Williams H (2002) New treatments for atopic dermatitis. BMY 324: 1533-1534
- Wohlrab J (2006) Calcineurin inhibitors for the topical therapy of psoriasis. dermatologist 57: 685-689
- Zabawski E (2002) Treatment of cutaneous lupus with Elidel. Dermatol Online J 8: 25